Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

Candel aims to submit BLA in 2026 as Lancet data reinforce prostate cancer potential

Aug 13, 2026, 8:08 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Material regulatory milestone (Q4 2026 BLA) plus positive phase 3 data (Lancet Oncology) and a broadened trial program (AURORA) create near-term upside if milestones are met; liquidity coverage into 2028 reduces funding risk, supporting a more favorable risk/reward.

AI summary

What happened, with direct paths to the underlying reporting

Candel Therapeutics reports a strong Q2 2026 with $201.6 million in cash and a plan to submit a BLA for aglatimagene in Q4 2026. The Lancet Oncology pivotal data show a meaningful disease-free survival improvement when aglatimagene is added to radiotherapy, supporting a potential 2027 US launch if approved. The AURORA NSCLC trial is now active, expanding the platform’s reach and near-term catalysts.

BLA planned for aglatimagene in localized prostate cancer in Q4 2026. Regulatory milestone.
Lancet Oncology pivotal phase 3 data show DFS improvement with aglatimagene plus radiotherapy.
AUA 2026 follow-up: 745 patients; aglatimagene DFS improvement of 39%.
AURORA NSCLC trial first site activated; global enrollment planned.
Cash and equivalents $201.6M as of 6/30/2026; runway into Q1 2028.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.